Repeated 177Lu-labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBq
Current treatment protocols for 177Lu-labeled PSMA-617 therapies were cautiously derived from dosimetry data, but their practical appropriateness has not yet been proven clinically. We retrospectively report our clinical observations using 4 different treatment activities. Methods: Forty patients wi...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
Journal of nuclear medicine
Year: 2017, Jahrgang: 59, Heft: 3, Pages: 459-465 |
| ISSN: | 2159-662X |
| DOI: | 10.2967/jnumed.117.194209 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.2967/jnumed.117.194209 Verlag, kostenfrei, Volltext: http://jnm.snmjournals.org/content/59/3/459 
|
| Verfasserangaben: | Hendrik Rathke, Frederik L. Giesel, Paul Flechsig, Klaus Kopka, Walter Mier, Markus Hohenfellner, Uwe Haberkorn, and Clemens Kratochwil |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1571841210 | ||
| 003 | DE-627 | ||
| 005 | 20230426124235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180409r20182017xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2967/jnumed.117.194209 |2 doi | |
| 035 | |a (DE-627)1571841210 | ||
| 035 | |a (DE-576)501841210 | ||
| 035 | |a (DE-599)BSZ501841210 | ||
| 035 | |a (OCoLC)1341001636 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Rathke, Hendrik |d 1986- |e VerfasserIn |0 (DE-588)1151445495 |0 (DE-627)1011715392 |0 (DE-576)497748223 |4 aut | |
| 245 | 1 | 0 | |a Repeated 177Lu-labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBq |c Hendrik Rathke, Frederik L. Giesel, Paul Flechsig, Klaus Kopka, Walter Mier, Markus Hohenfellner, Uwe Haberkorn, and Clemens Kratochwil |
| 264 | 1 | |c 2018 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online Aug. 10, 2017 | ||
| 500 | |a Im Titel ist "177" in 177Lu-labeled hochgestellt | ||
| 500 | |a Gesehen am 09.04.2018 | ||
| 520 | |a Current treatment protocols for 177Lu-labeled PSMA-617 therapies were cautiously derived from dosimetry data, but their practical appropriateness has not yet been proven clinically. We retrospectively report our clinical observations using 4 different treatment activities. Methods: Forty patients with advanced prostate cancer and positive uptake in prostate-specific membrane antigen (PSMA) imaging were treated with 4 GBq of 177Lu activity/80 nmol of precursor, 6 GBq of 177Lu activity/120 nmol of precursor, 7.4 GBq of 177Lu activity/150 nmol of precursor, or 9.3 GBq of 177Lu activity/150 nmol of precursor (10 patients per group) every 2 mo. Safety was checked every 2 wk by laboratory tests, the prostate-specific antigen response was checked every 4 wk, and other effects were assessed by anamnesis. Results: The initial prostate-specific antigen response showed no correlation with treatment activity. However, 2 of 10, 4 of 10, 4 of 10, and 7 of 10 patients receiving doses of 4, 6, 7.4, and 9.3 GBq, respectively, were in partial remission 8 wk after completing all 3 cycles. This finding would be in line with but—because of low patient numbers—would not prove a positive dose-response relationship. Acute hematologic toxicity was also not correlated with treatment activity, and no more than 1 patient per group had grade 3/4 toxicity. Nevertheless, in contrast to the findings for the other groups, the mean platelet count in the 9.3-GBq group decreased chronically over time. Conclusion: If patients with diffuse red marrow infiltration and extensive chemotherapeutic pretreatments are excluded, then treatment activities of up to 3 injections of 9.3 GBq of 177Lu-PSMA-617 every 2 mo are tolerated well. Further dose escalation should be conducted with care, as the highest dose seems to be close to the maximum tolerable dose. | ||
| 534 | |c 2017 | ||
| 650 | 4 | |a 177Lu | |
| 650 | 4 | |a 177Lu-PSMA-617 | |
| 650 | 4 | |a metastasized castration-resistant prostate cancer | |
| 650 | 4 | |a PSMA-RLT | |
| 700 | 1 | |a Giesel, Frederik L. |d 1970- |e VerfasserIn |0 (DE-588)129031240 |0 (DE-627)387883878 |0 (DE-576)297457071 |4 aut | |
| 700 | 1 | |a Flechsig, Paul |d 1983- |e VerfasserIn |0 (DE-588)141881224 |0 (DE-627)632461527 |0 (DE-576)325791430 |4 aut | |
| 700 | 1 | |a Mier, Walter |d 1966- |e VerfasserIn |0 (DE-588)12029026X |0 (DE-627)69653567X |0 (DE-576)292141599 |4 aut | |
| 700 | 1 | |a Hohenfellner, Markus |d 1958- |e VerfasserIn |0 (DE-588)133862518 |0 (DE-627)557857988 |0 (DE-576)300155263 |4 aut | |
| 700 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 700 | 1 | |a Kratochwil, Clemens |d 1978- |e VerfasserIn |0 (DE-588)134026276 |0 (DE-627)559871686 |0 (DE-576)300262787 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nuclear medicine |d New York, NY : Soc., 1964 |g 59(2018), 3, Seite 459-465 |h Online-Ressource |w (DE-627)325793603 |w (DE-600)2040222-3 |w (DE-576)09475277X |x 2159-662X |7 nnas |a Repeated 177Lu-labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBq |
| 773 | 1 | 8 | |g volume:59 |g year:2018 |g number:3 |g pages:459-465 |g extent:7 |a Repeated 177Lu-labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBq |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2967/jnumed.117.194209 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://jnm.snmjournals.org/content/59/3/459 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180409 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 134026276 |a Kratochwil, Clemens |m 134026276:Kratochwil, Clemens |d 910000 |d 911400 |e 910000PK134026276 |e 911400PK134026276 |k 0/910000/ |k 1/910000/911400/ |p 8 |y j | ||
| 998 | |g 1022913905 |a Haberkorn, Uwe |m 1022913905:Haberkorn, Uwe |d 910000 |d 911400 |e 910000PH1022913905 |e 911400PH1022913905 |k 0/910000/ |k 1/910000/911400/ |p 7 | ||
| 998 | |g 133862518 |a Hohenfellner, Markus |m 133862518:Hohenfellner, Markus |d 910000 |d 910200 |e 910000PH133862518 |e 910200PH133862518 |k 0/910000/ |k 1/910000/910200/ |p 6 | ||
| 998 | |g 12029026X |a Mier, Walter |m 12029026X:Mier, Walter |d 910000 |d 911400 |e 910000PM12029026X |e 911400PM12029026X |k 0/910000/ |k 1/910000/911400/ |p 5 | ||
| 998 | |g 141881224 |a Flechsig, Paul |m 141881224:Flechsig, Paul |d 50000 |e 50000PF141881224 |k 0/50000/ |p 3 | ||
| 998 | |g 129031240 |a Giesel, Frederik L. |m 129031240:Giesel, Frederik L. |d 910000 |d 911400 |e 910000PG129031240 |e 911400PG129031240 |k 0/910000/ |k 1/910000/911400/ |p 2 | ||
| 998 | |g 1151445495 |a Rathke, Hendrik |m 1151445495:Rathke, Hendrik |d 910000 |d 911400 |e 910000PR1151445495 |e 911400PR1151445495 |k 0/910000/ |k 1/910000/911400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1571841210 |e 3005390039 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title_sort":"Repeated 177Lu-labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBq","title":"Repeated 177Lu-labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBq"}],"person":[{"role":"aut","display":"Rathke, Hendrik","given":"Hendrik","family":"Rathke"},{"family":"Giesel","given":"Frederik L.","display":"Giesel, Frederik L.","role":"aut"},{"display":"Flechsig, Paul","given":"Paul","family":"Flechsig","role":"aut"},{"family":"Mier","given":"Walter","display":"Mier, Walter","role":"aut"},{"role":"aut","family":"Hohenfellner","given":"Markus","display":"Hohenfellner, Markus"},{"given":"Uwe","display":"Haberkorn, Uwe","family":"Haberkorn","role":"aut"},{"family":"Kratochwil","given":"Clemens","display":"Kratochwil, Clemens","role":"aut"}],"recId":"1571841210","origin":[{"dateIssuedDisp":"2018","dateIssuedKey":"2018"}],"name":{"displayForm":["Hendrik Rathke, Frederik L. Giesel, Paul Flechsig, Klaus Kopka, Walter Mier, Markus Hohenfellner, Uwe Haberkorn, and Clemens Kratochwil"]},"relHost":[{"corporate":[{"role":"isb","display":"Society of Nuclear Medicine"}],"name":{"displayForm":["Society of Nuclear Medicine"]},"origin":[{"dateIssuedDisp":"1964-","publisher":"Soc.","publisherPlace":"New York, NY","dateIssuedKey":"1964"}],"title":[{"title":"Journal of nuclear medicine","title_sort":"Journal of nuclear medicine","subtitle":"JNM"}],"part":{"issue":"3","extent":"7","pages":"459-465","year":"2018","text":"59(2018), 3, Seite 459-465","volume":"59"},"id":{"zdb":["2040222-3"],"issn":["2159-662X","1535-5667"],"eki":["325793603"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 13.12.2021"],"disp":"Repeated 177Lu-labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBqJournal of nuclear medicine","recId":"325793603","titleAlt":[{"title":"JNM"}],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["Nachgewiesen 5.1964 -"]}],"note":["Published online Aug. 10, 2017","Im Titel ist \"177\" in 177Lu-labeled hochgestellt","Gesehen am 09.04.2018"],"physDesc":[{"extent":"7 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.2967/jnumed.117.194209"],"eki":["1571841210"]}} | ||
| SRT | |a RATHKEHENDREPEATED172018 | ||